Currently, there are 215.21M common shares owned by the public and among those 200.63M shares have been available to trade.
The company’s stock has a 5-day price change of -0.41% and 56.69% over the past three months. HIMS shares are trading 132.96% year to date (YTD), with the 12-month market performance up to 170.43% higher. It has a 12-month low price of $13.47 and touched a high of $72.98 over the same period. HIMS has an average intraday trading volume of 37.44 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.77%, 34.48%, and 79.41% respectively.
Institutional ownership of Hims & Hers Health Inc (NYSE: HIMS) shares accounts for 70.31% of the company’s 215.21M shares outstanding.
It has a market capitalization of $12.61B and a beta (3y monthly) value of 2.10. The stock’s trailing 12-month PE ratio is 81.99, while the earnings-per-share (ttm) stands at $0.69. The company has a PEG of 2.37 and a Quick Ratio of 1.32 with the debt-to-equity ratio at 0.12. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.57% over the week and 5.79% over the month.
Analysts forecast that Hims & Hers Health Inc (HIMS) will achieve an EPS of 0.22 for the current quarter, 0.26 for the next quarter and 1.38 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.18 while analysts give the company a high EPS estimate of 0.18. Comparatively, EPS for the current quarter was 0.16 a year ago. Earnings per share for the fiscal year are expected to increase by 24.89%, and 44.17% over the next financial year. EPS should grow at an annualized rate of 34.57% over the next five years, compared to 17.22% over the past 5-year period.
Looking at the support for the HIMS, a number of firms have released research notes about the stock. Needham stated their Buy rating for the stock in a research note on June 04, 2025, with the firm’s price target at $61-$65. TD Cowen coverage for the Hims & Hers Health Inc (HIMS) stock in a research note released on April 29, 2025 offered a Hold rating with a price target of $30. Morgan Stanley was of a view on February 18, 2025 that the stock is Equal-Weight, while Citigroup gave the stock Sell rating on January 10, 2025, issuing a price target of $24- $25. BTIG Research on their part issued Buy rating on January 07, 2025.
